Details of the Drug Combinations

General Information of This Drug (ID: DMZRXTL)

Drug Name

E7820 DMZRXTL

Synonyms

E7820; 289483-69-8; E-7820; E 7820; UNII-TVH5K7949N; TVH5K7949N; 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide; NSC-719239; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-; LWGUASZLXHYWIV-UHFFFAOYSA-N; AC1L52N5; ZINC8704; SCHEMBL1581157; DTXSID20183142; BCP25835; EX-A1818; 3-Cyano-N-(3-cyano-4-methyl-1H-indole-7-yl)benzensulfonamide; NSC719239; AKOS032944953; CS-6075

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

6 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ATI-17000 + E7820	DC2LRXO	ATI-17000	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
E7820 + Trametinib	DCUMLIZ	Trametinib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
E7820 + Panobinostat	DCEBK4S	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Marimastat + E7820	DCWOTHC	Marimastat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
PHA848125 + E7820	DCUJH7X	PHA848125	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Prochlorperazine + E7820	DCBKASB	Prochlorperazine	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DrugCom(s)

References

1	ClinicalTrials.gov (NCT00309179) A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors. U.S. National Institutes of Health.
2	Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200.
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.